News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
203,209 Results
Type
Article (19835)
Company Profile (110)
Press Release (183264)
Section
Business (65658)
Career Advice (886)
Deals (9593)
Drug Delivery (69)
Drug Development (19630)
Employer Resources (137)
FDA (3522)
Job Trends (6106)
News (98920)
Policy (7736)
Tag
Academia (1507)
Alliances (17703)
Alzheimer's disease (498)
Antibody-drug conjugate (ADC) (47)
Approvals (3493)
Artificial intelligence (77)
Bankruptcy (47)
Best Places to Work (4973)
Biosimilars (46)
Biotechnology (67)
Breast cancer (41)
Cancer (352)
Cardiovascular disease (53)
Career advice (772)
Cell therapy (96)
Clinical research (14724)
Collaboration (201)
COVID-19 (1001)
C-suite (58)
Data (379)
Diabetes (55)
Diagnostics (2358)
Drug pricing (52)
Earnings (15227)
Employer resources (117)
Events (29894)
Executive appointments (173)
FDA (3679)
Funding (175)
Gene therapy (73)
GLP-1 (291)
Government (1380)
Healthcare (5217)
Infectious disease (1040)
Inflammatory bowel disease (45)
Interviews (124)
IPO (3858)
Job creations (1325)
Job search strategy (671)
Layoffs (146)
Legal (1510)
Lung cancer (59)
Management (41)
Manufacturing (86)
Medical device (2921)
Medtech (2925)
Mergers & acquisitions (5830)
Metabolic disorders (168)
Neuroscience (609)
NextGen Class of 2024 (2199)
Non-profit (1719)
Northern California (514)
Obesity (107)
Opinion (92)
People (26917)
Phase I (4219)
Phase II (5982)
Phase III (5974)
Pipeline (126)
Postmarket research (647)
Preclinical (2406)
Press Release (61)
Radiopharmaceuticals (65)
Rare diseases (75)
Real estate (2544)
Recruiting (53)
Regulatory (5241)
Research institute (1272)
Resumes & cover letters (138)
Southern California (326)
Startups (2010)
United States (4267)
Vaccines (179)
Weight loss (86)
Date
Today (38)
Last 7 days (110)
Last 30 days (961)
Last 365 days (12095)
2024 (11313)
2023 (13445)
2022 (16157)
2021 (18418)
2020 (16982)
2019 (15721)
2018 (11398)
2017 (10801)
2016 (10638)
2015 (11286)
2014 (8383)
2013 (7218)
2012 (7590)
2011 (7808)
2010 (7310)
Location
Africa (336)
Arizona (57)
Asia (11395)
Australia (2089)
California (1011)
Canada (410)
China (84)
Colorado (57)
Europe (29547)
Florida (139)
Illinois (102)
Indiana (90)
Maryland (137)
Massachusetts (860)
Michigan (66)
Minnesota (105)
New Jersey (335)
New York (381)
North Carolina (240)
Northern California (514)
Ohio (46)
Pennsylvania (173)
South America (496)
Southern California (326)
Texas (144)
Washington State (87)
203,209 Results for "cv sciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CVS Health Announces Board Appointments
November 18, 2024
·
7 min read
Press Releases
CVS Health announces Pharmacy and Consumer Wellness leadership appointments
December 3, 2024
·
3 min read
GLP-1
Novo Scores Late-Stage CV Win for Rybelsus on Heels of Wegovy Label Expansion
Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
October 21, 2024
·
1 min read
·
Heather McKenzie
Drug Delivery
Sandoz’s Biosimilar Skyrockets After CVS Removes AbbVie’s Humira from Formularies
Prescriptions for Sandoz’s Hyrimoz, a biosimilar version of AbbVie’s Humira, have shot up after CVS Caremark took the blockbuster arthritis treatment off its major national commercial formularies on April 1.
April 16, 2024
·
2 min read
·
Tristan Manalac
BioMidwest
Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System
Aria CV, Inc today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St. Vincent Cardiovascular Research Institute in Indianapolis, Indiana.
February 27, 2024
·
3 min read
Press Releases
DAXOR’S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL ’24
October 9, 2024
·
3 min read
FDA
XCOPRI® (cenobamate tablets) CV Receives FDA Approval for Alternate Methods of Administration That Include Crushed Tablet in Liquid Suspension Taken Orally or Through a Nasogastric Tube
SK Life Science, Inc. today announced the U.S. Food and Drug Administration (FDA) approved two new administration options of XCOPRI® (cenobamate tablets) CV, an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, which can now be crushed and mixed with water and either administered by mouth as an oral suspension or administered via a nasogastric tube.
April 11, 2024
·
10 min read
Press Releases
CV6 Therapeutics Announces Initiation of Patient Dosing in Phase 1a Clinical Trial Evaluating the Investigational First-In-Class, Specific dUTPase Inhibitor CV6-168
August 15, 2024
·
3 min read
Pharm Country
SK Life Science Announces Data Presentations for XCOPRI® (cenobamate tablets) CV at the 2024 American Academy of Neurology Annual Meeting
SK Life Science, Inc. today announced the schedule for two oral and six poster presentations at the American Academy of Neurology (AAN) Annual Meeting taking place April 13–18, 2024, virtually and in-person in Denver, Colorado.
April 9, 2024
·
11 min read
Business
Genomma Lab Internacional S.A.B. de C.V. First Quarter 2024 Earnings Results Conference Call
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”) today announced that it will report its First Quarter 2024 Earnings Results on Wednesday, April 24, 2024, after the Mexican Stock Exchange (BMV) close.
April 4, 2024
·
2 min read
1 of 20,321
Next